series-b
Stage
2
Investors
About
Inhibrx is a clinical-stage biopharmaceutical company that designs and develops biologic therapeutics using a proprietary single-domain antibody and protein-engineering platform, advancing targeted immunotherapies for serious and life-threatening conditions.
Explore Inhibrx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.